Skip to content
DataLookout
Menu

NCT04177004

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words
    • Primary endpoints: details revised at 1 of 4 entries
    • Study completion pushed from Oct 27, 2026 to Mar 23, 2027
    • Secondary endpoints: details revised at 15 of 15 entries
  2. Minor Primary completion moved earlier from Oct 27, 2026 to Dec 29, 2025v15
  3. Notable Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: estimated 53 to confirmed 52
    v14
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Accrual goal met
    • Site details revised
    v13
  5. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Oct 27, 2025 to Oct 27, 2026
    • Enrollment target: 43 to 53
    • Site details revised
    v12
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 36 to confirmed 43
    • Site details revised
    v11
  2. Notable Primary and study completion dates: Dec 31, 2024 to Oct 27, 2025v10
  3. Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v9
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
    • Start date changed from estimate of May 15, 2021 to Apr 30, 2021
    • Site details revised
    v6
  5. Notable Primary and study completion dates: Jul 29, 2021 to Dec 31, 2022
    • Start date: Jan 15, 2021 to May 15, 2021
    v5
  6. Notable Start date: Jul 1, 2020 to Jan 15, 2021v4
  7. Notable Start date: Apr 1, 2020 to Jul 1, 2020v3
  8. Notable Start date: Jan 1, 2020 to Apr 1, 2020v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Patients' ability to drink the specified daily amount of 750 ml human lysozyme goat milk (hLZ)
Timeframe: from study initiation until up to 28 days post-transplant or until discharge, whoever comes first
Unacceptable toxicity
Timeframe: Up to 28 days post-transplant or date of discharge
Adverse events
Timeframe: Up to 100 days post-transplant
Volume of hLZ consumed
Timeframe: Up to 28 days post-transplant or date of discharge

Secondary (9)

Cumulative incidence (CI) of chronic graft versus host disease (GVHD)
Cumulative incidence (CI) of chronic GVHD
CI of non-relapse mortality (NRM)
CI of NRM
CI of relapse/progression
Show 4 moreShow less
Gut microbiome diversity
CI of acute graft versus host disease (aGVHD)
Incidence of bloodstream infections
Overall survival (OS)

Arms and interventions

Group A (conditioning, goat milk, transplant, prophylaxis)Experimental

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity. HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity. TRANSPLANT: Patients undergo stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Group B (conditioning, transplant, prophylaxis)Active comparator

CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity. TRANSPLANT: Patients undergo stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.

Procedures: Allogeneic Hematopoietic Stem Cell Transplantation

Drugs: Cyclophosphamide, Etoposide, Goat Milk, Sirolimus, Tacrolimus

Radiation: Fractionated Stereotactic Radiation Therapy

Biologicals: Palifermin

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States